MedTrace Logo

NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia

NCT04870866 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2022-08-17

No results posted yet for this study

Summary

The study investigates the effect of dietary supplementation of nicotinamide ribonucleoside (NR) in children with ataxia telangiectasia (AT), with main focus on neurological symptoms.

Conditions

  • Ataxia Telangiectasia

Interventions

DRUG

Nicotinamide ribonucleoside

Two year intervention

Sponsors & Collaborators

  • The Bergesen Foundation

    collaborator OTHER

  • South-Eastern Norway Regional Health Authority

    collaborator OTHER

  • Sykehuset Innlandet HF

    collaborator OTHER

  • Oslo University Hospital

    collaborator OTHER

  • St. Olavs Hospital

    collaborator OTHER

  • Haukeland University Hospital

    collaborator OTHER

  • University Hospital of North Norway

    collaborator OTHER

  • University of Bergen

    collaborator OTHER

  • University Hospital, Akershus

    lead OTHER

Principal Investigators

  • Hilde L Nilsen · University Hospital, Akershus

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-05
Primary Completion
2024-09-03
Completion
2027-06-16
FDA Drug
Yes

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04870866 on ClinicalTrials.gov